

# UC San Diego

## UC San Diego Previously Published Works

### Title

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

### Permalink

<https://escholarship.org/uc/item/1dx8x8xw>

### Authors

Chen, Qiuqiang

Jia, Gang

Zhang, Xilin

et al.

### Publication Date

2024

### DOI

10.3389/fimmu.2024.1376045

Peer reviewed



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Qiuqiang Chen

✉ [chenqiuq@hotmail.com](mailto:chenqiuq@hotmail.com)

Wenxue Ma

✉ [wma@health.ucsd.edu](mailto:wma@health.ucsd.edu)

RECEIVED 24 January 2024

ACCEPTED 25 January 2024

PUBLISHED 31 January 2024

## CITATION

Chen Q, Jia G, Zhang X and Ma W (2024)  
Corrigendum: Targeting HER3 to overcome  
RGFR TKI resistance in NSCLC.  
*Front. Immunol.* 15:1376045.  
doi: 10.3389/fimmu.2024.1376045

## COPYRIGHT

© 2024 Chen, Jia, Zhang and Ma. This is an  
open-access article distributed under the terms  
of the [Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction  
in other forums is permitted, provided the  
original author(s) and the copyright owner(s)  
are credited and that the original publication  
in this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen<sup>1\*</sup>, Gang Jia<sup>2</sup>, Xilin Zhang<sup>1</sup> and Wenxue Ma<sup>3\*</sup>

<sup>1</sup>Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China, <sup>2</sup>Department of Medical Oncology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China, <sup>3</sup>Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, United States

## KEYWORDS

non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR), tyrosine kinase inhibitors (TKIs), receptor tyrosine kinases (RTKs), resistance, human EGFR3 (HER3), antibody-drug conjugates (ADCs), Patritumab Deruxtecan (HER3-DXd)

## A Corrigendum on

## Targeting HER3 to overcome EGFR TKI resistance in NSCLC

By Chen Q, Jia G, Zhang X, and Ma W (2024) *Front. Immunol.* 14:1332057. doi: 10.3389/fimmu.2023.1332057

In the published article, there was an error in affiliation 1. Instead of “1”, it should be “3” only for the corresponding author Wenxue Ma. The correct affiliations of the authors are listed below.

**Qiuqiang Chen<sup>1\*</sup>, Gang Jia<sup>2</sup>, Xilin Zhang<sup>1</sup>, Wenxue Ma<sup>3\*</sup>**

<sup>1</sup> Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China

<sup>2</sup> Department of Medical Oncology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China

<sup>3</sup> Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, United States

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.